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Abstract
In this longitudinal study we investigated change over time in cerebrospinal fluid (CSF) levels of amyloid-beta 40 and 42 (A40 and
A42), total tau (tau), tau phosphorylated at threonine 181 (ptau-181), isoprostane, neurofilaments heavy (NfH) and light (NfL).
wenty-four nondemented subjects, 62 mild cognitive impairment (MCI) and 68 Alzheimer’s disease (AD) patients underwent 2 lumbar
unctures, with minimum interval of 6, and a mean  SD of 24  13 months. Linear mixed models were used to assess change over time.
myloid-beta 42, tau, and tau phosphorylated at threonine 181, differentiated between diagnosis groups (p  0.05), whereas isoprostane,
eurofilaments heavy, and NfL did not. In contrast, effects of follow-up time were only found for nonspecific CSF biomarkers: levels of
fL decreased, and levels of isoprostane, amyloid-beta 40, and tau increased over time (p  0.05). Isoprostane showed the largest increase.
n addition, increase in isoprostane was associated with progression of mild cognitive impairment to AD, and with cognitive decline as
eflected by change in Mini Mental State Examination (MMSE). Contrary to AD-specific markers, nonspecific CSF biomarkers, most
otably isoprostane, showed change over time. These markers could potentially be used to monitor disease progression in AD.
2012 Elsevier Inc.
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M1. Introduction
Major efforts are under way to investigate therapeutic
strategies that have the potential to slow progression of
Alzheimer’s disease (AD). To evaluate the effect of these
interventions, biological markers are needed that reflect
progression of AD pathology.
The major pathological hallmarks of AD are senile
plaques, containing beta-amyloid and neurofibrillary tangles
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VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The
Netherlands. Tel.: 31 20 4440742; fax: 31 20 4440715.E-mail address: m.kester@vumc.nl (M.I. Kester).
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Open access under the Elsevier OA license.with microtubule-associated tau protein (McKhann et al.,
1984). Cerebrospinal fluid (CSF) biomarkers amyloid-beta
1–42 (A42), total tau (tau), and tau phosphorylated at
hreonine 181 (ptau-181) reflect the neuropathology of AD
nd are useful as diagnostic markers for AD (Blennow and
ampel, 2003). Several studies evaluated whether these
arkers could also be used as markers to monitor disease
rogression, but until now these biomarkers showed little
ffect in longitudinal settings (Blennow et al., 2007; Bou-
man et al., 2007; Buchhave et al., 2009; Li et al., 2007;
ollenhauer et al., 2005; Zhou et al., 2009).
The specific biomarkers, amyloid-beta 42 (A42), total
tau (tau) and ptau-181, seem less suitable as biomarkers for
monitoring of disease progression. Amyloid plaque deposi-
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1592 M.I. Kester et al. / Neurobiology of Aging 33 (2012) 1591–1598tion and tau tangle formation are early processes in AD, that
may show little or no change later on (Jack et al., 2010).
Other, more general and thus less specific disease processes
are increasingly considered to play a major role in advanced
stages of the disease (Jack et al., 2010). Oxidative stress
damage is a process of neurotoxicity due to free radical-
mediated damage to cellular membranes, which probably
also occurs in advanced stages of AD (Quinn et al., 2004).
Isoprostane, an oxidative stress marker, therefore, could be
a useful marker to monitor AD. In fact, a few small studies
have shown increase over time in isoprostane (de Leon et
al., 2007; Montine et al., 2005; Quinn et al., 2004). Neuro-
filaments are released from damaged neurons. CSF levels of
neurofilaments have been shown to reflect the degree of
neuronal degeneration and axonal loss in several neurolog-
ical diseases (de Jong et al., 2007; Petzold, 2005). Few
cross-sectional studies have shown increased levels of neu-
rofilaments in AD (Norgren et al., 2003; Pijnenburg et al.,
2007), and possibly changes in the levels of neurofilaments
also reflect progression of the disease. Furthermore, we
hypothesized that CSF amyloid-beta n-40 (A40) could be
biomarker for disease progression, because A40 has been
ssociated with solid, less diffuse, types of amyloid plaques,
hat generally develop in later stages of AD (Iwatsubo et al.,
994; Kumar-Singh, 2008).
We aimed to assess longitudinal effects of CSF biomark-
rs, in order to identify biomarkers that are useful to monitor
isease progression. Our panel of 7 CSF biomarkers in-
luded A42, tau and ptau-181, and several less specific
CSF biomarkers, isoprostane, neurofilaments heavy (NfH),
neurofilaments light (NfL), and A40. We evaluated
hanges in CSF biomarker levels over time, and associa-
ions of change in CSF biomarker levels with change in
ini Mental State Examination (MMSE), in a large cohort
f AD and mild cognitive impairment (MCI) patients and
ondemented subjects.
. Methods
.1. Patients
We included patients with AD (n  68), MCI (n  62),
and nondemented subjects (n  24) with CSF at 2 time
points. At baseline all patients underwent standard dementia
screening including physical and neurological examination,
laboratory tests, electroencephalogram (EEG), and mag-
netic resonance imaging (MRI). Cognitive screening in-
cluded an MMSE, but usually involved comprehensive neu-
ropsychological testing. The diagnosis of probable AD was
made according to National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) criteria (McKhann et al., 1984). The diagnosis of
MCI was made according to Petersen’s criteria (Petersen et
al., 1999). When the results of all examinations were nor-
mal, patients were considered to have subjective com-plaints. The nondemented subjects group consisted of 20
patients with subjective memory complaints, 2 patients with
a psychiatric disorder, and 2 patients with temporal epi-
lepsy. Diagnoses were made by consensus in a multidisci-
plinary team. The study was approved by the local ethical
review board and all subjects gave written informed con-
sent.
2.2. Follow-up
At follow-up, patients were asked to undergo a second
lumbar puncture (minimum interval 6 months). Within the
MCI group, 21 patients remained stable, and 34 progressed
to AD (McKhann et al., 1984), 3 to fronto-temporal lobar
degeneration (FTLD; Neary et al., 1998), 2 to vascular
dementia (VaD; Román et al., 1993), 1 to dementia with
Lewy bodies (DLB; McKeith et al., 2005), and 1 was
diagnosed with normal pressure hydrocephalus. Within the
24 nondemented subjects, 6 patients with subjective com-
plaints progressed to MCI, 2 to AD, and 1 to vascular
dementia, while 15 remained stable. We used the last avail-
able MMSE to estimate cognitive decline over time (MMSE
at follow-up available in 19 nondemented, 55 MCI, and 56
AD subjects).
2.3. CSF analyses
CSF was obtained by lumbar puncture, using a 25-gauge
needle, and collected in 10-mL polypropylene tubes. Within
2 hours, CSF samples were centrifuged at 1800g for 10
inutes at 4° C. CSF was aliquoted in polypropylene tubes
f 0.5 or 1 mL and stored at 80° C until further analysis.
o circumvent interassay variability, baseline and follow-up
amples were analyzed in the same assay (Bouwman et al.,
006; Verwey et al., 2008). CSF A42, tau, and ptau-181
ere measured with Innotest Luminex (Bouwman et al.,
009). Intra-assay coefficients of variation (CV) were 5.1%
or A42, 3.4% for tau, and 4.1% for ptau-181. Inter-assay
CV’s were 5.6% at 55 pg/mL and 5.5% at 133 pg/mL for
A42, 5.9% at 75 pg/mL and 6.4% at 215 pg/mL for tau,
and 4.4% at 30 pg/mL and 3.6% at 47 pg/mL for ptau-181
(n  10). A40 was measured with an in-house method
Verwey et al., 2009). The detection limit was 0.39 ng/mL
3 SD [standard deviations] above background; %CV 
0%). For A40 intra-assay CV was 1.9%, and interassay
CV was 10.7% at 4.71 ng/mL and 4.7% at 9.56 ng/mL (n 
10). NfL was determined by enzyme-linked immunosorbent
assay (ELISA) essentially as described before (Norgren et
al., 2004), however the first antibody was replaced by the
in-house produced anti-neurofilament monoclonal antibody,
clone 4F8. The detection limit was 0.095 ng/mL. For NfL
intra-assay CV was 9.5% and interassay CV was 27.5% at
4.78 ng/mL (n  9). NfH was measured in an in-house
developed multiplex assay. Activated beads from Qiagen
(Hilden, Germany) were covalently immobilized with an
anti-neurofilament monoclonal antibody (9C9 generously
provided by Carsten Korth, Germany). After blocking Du-
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lerica, MA, USA) with phosphate-buffered saline (PBS)/1%
bovine serum albumin (BSA)/0.05% Tween-20, 50 L of
tandard (NFH; Progen, Heidelberg, Germany), controls,
SF samples, and blanks were incubated with a suspension
f microspheres (2500 beads per well) coupled with the
apturing antibody for 14–18 hours at 4° C on an orbital
late shaker (600 rpm). All further incubations were per-
ormed under continuous shaking (600 rpm) at room tem-
erature. CSF samples were diluted 5 times in PBS/1%
SA/6 mM ethylenediaminetetraacetic acid (EDTA). After
ashing with PBS/1%BSA/0.05% Tween-20, the wells
ere incubated with 25 L of 1:1000 diluted anti-neuro-
filament polyclonal antibody (#N4142, Sigma, The Nether-
lands). After washing, wells were incubated with 50 L of
:200 diluted Phycoerythrin-labeled donkey-anti-rabbit
olyclonal antibody (Jackson ImmunoResearch, West
rove, PA, USA). The plate was washed again and 100 L
eading solution (Bio-plex Sheath fluid; Bio-Rad, Hercules,
A, USA) was applied. The resulting fluorescence intensity
ignal on the specific bead was read with Bio-Plex 200
ystem (Bio-Rad; 50–100 microspheres). All analyses were
erformed in duplicate and normalized. Detection limit for
fH was 8.84 pg/mL 0.61. Intra-assay CV was 5.7%, and
nterassay CV was 18.3.% at 1774 pg/mL and 23.9% at
1131 pg/mL (n  9). The concentration of isoprostane
iPF2-VI) was determined by liquid chromatography tan-
dem mass spectrometry (LC-MS/MS). In brief, 0.1 mL of 2
ng/mL deuterated internal standard (8iPF2-d4; Cayman
Chemical, Ann Arbor, MI, USA; cat. 316300) was added to
0.5 mL CSF. Butylated hydroxytoluene (BHT) was added to
a final concentration of 0.05% to prevent arachidonic acid
from auto-oxidation during sample clean-up. Then 0.5 mL
of 2.6 M potassium hydroxide (KOH) was added, and sam-
ples were incubated for 60 minutes at 40° C. Afterwards,
formic acid (20%) was added to adjust the pH to approxi-
mately 4.5, and the sample was loaded onto a solid phase
extraction column (Oasis HLB, Etten-Leur, The Nether-
lands; Roest et al., 2008). The eluate was taken to dryness
under a stream of nitrogen at room temperature, and the
sample was redissolved in 100 L 10% acetonitrile in
water. Isoprostane concentrations were quantified by a 4000
Qtrap (AB SCIEX, Toronto, Canada) mass spectrometer.
To calculate the isoprostane concentration, the analyte/in-
ternal standard peak area ratio was compared with a stan-
dard curve from 2 to 16 ng/mL isoprostane (Cayman Chem-
ical; cat. 16300). Intrarun CV was 4.8%, and interrun CV
7.6% at 199 ng/mL and 10.1% at 43 pg/mL (n  17).
soprostane was measured in 146 patients.
.4. Statistical analysis
Differences between diagnosis categories were assessed
sing analysis of variance (ANOVA) with post hoc Bonfer-
oni corrections or Fisher exact test when applicable. Pear-
on correlations were used to assess correlations betweenontinuous variables. Age- and sex-adjusted linear mixed
odels were applied to assess baseline effects for diagnosis
nd changes over time in CSF biomarkers by diagnosis. The
SF biomarkers (A40, A42, tau, ptau-181, NfL, NfH,
and isoprostane ) were the dependent variables (each in
separate model), while diagnosis (treated as categorical
variable) and time (in years; treated as a continuous vari-
able) and interaction between diagnosis and time were in-
dependent variables. Diagnosis categories were recoded to
be able to estimate  standard errors (SE) for all diagnosis
categories. A random intercept and random slope with time
were assumed. For visualization purposes and to allow
comparison of the effect sizes of the different CSF biomark-
ers, standardized ’s were calculated with the formula 
biomarker  SD time/SD biomarker. Additional analyses
were performed to analyze change in CSF biomarker levels
over time in relation to progression of MCI. For this anal-
ysis patients with stable MCI and patients that progressed
from MCI to AD were included. An age- and sex-adjusted
mixed model was used with CSF biomarkers (each in sep-
arate model) as dependent variable and MCI subgroup
(dummies for MCI stable and MCI progression), time, and
the interaction between MCI subgroups and time as inde-
pendent variables. Finally, for biomarkers that showed
change over time, we calculated the annualized changes of
CSF biomarker level and MMSE, with the formula value of
measurement at follow-up minus value of measurement at
baseline, divided by follow-up period in years. Associations
between annualized change in CSF biomarker levels and
annualized change in MMSE score were assessed using
linear regression models (data available for 130 patients),
adjusted for sex, age, and diagnosis. Statistical significance
was set at p  0.05.
Table 1
Patient characteristics for the separate diagnosis categories
Nondemented
(n  24)
MCI
(n  62)
AD
(n  68)
Age (years) 64  10 68  8 65  7
Sex, n (%) female 7 (29%) 23 (37%) 31 (46%)
Follow-up time (years) 2.5  1.7 2.0  1.1 1.9  1.0
MMSE baseline 28  2 26  2 22  5*,**
MSE follow-upa 27  3 22  5* 16  7*,**
MSE follow-up time (years) 4.0 2.7 3.8  2.1 3.2  2.0
Medical history
TIA or stroke, n (%) 3 (13%) 7 (11%) 2 (3%)
Hypertension, n (%) 8 (33%) 16 (26%) 12 (18%)
Hypercholesterolemia, n (%) 5 (21%) 7 (11%) 8 (12%)
Diabetes Mellitus, n (%) 1 (4%) 5 (8%) 1 (2%)
Data are represented as mean  SD unless indicated otherwise.
Key: AD, Alzheimer’s disease; MCI, mild cognitive impairment; MMSE,
Mini Mental State Examination; SD, standard deviation; TIA, transient
ischemic attack.
a Follow-up MMSE was available for 130 patients, and follow-up period
was generally longer than for lumbar puncture.
* p  0.005 versus nondemented subjects.
** p  0.005 versus MCI.
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Table 1 presents the patient characteristics according
to diagnosis. Patients with AD had a lower score on
baseline MMSE, compared with nondemented subjects
and MCI patients. Mean (SD) annual change in MMSE
was 0.4 (1.0) for nondemented patients, 1.2 (1.9) for
MCI patients and 2.2 (1.9) for AD patients. At baseline
here were no correlations between CSF biomarker levels
nd storage time, but levels of isoprostane (r  0.20; p 
.05) and NfH (r  0.39; p  0.001) were positively
orrelated with age.
We used linear mixed models to investigate the effects
f diagnosis and time on CSF biomarker levels of A42,
tau, ptau-181, isoprostane, NfH, NfL, and A40. Age-
and sex-adjusted analyses were performed with diagnosis
as categorical variable and time as continuous variable,
with an interaction term for diagnosis  time. There was
a main effect of diagnosis for A42, tau, ptau-181, and
A40 at baseline, whereas the biomarkers isoprostane,
fH, and NfL did not differentiate between diagnosis
roups at baseline (Table 2).
Change in CSF biomarker levels over time, was found
or isoprostane, NfH, NfL, A40, and tau, but not for A42
Table 2
Baseline levels and change over time of CSF biomarker levels
Nondemented (n 
A42 (pg/mL), baseline 403  125
42 (pg/mL), follow-up 399  135
Annual change,  (SE) 1.9 (4.3)
Tau (pg/mL), baseline 104  59
Tau (pg/mL), follow-up 121  87
Annual change,  (SE) 4.9 (3.4)
Ptau-181 (pg/mL), baseline 31  17
Ptau-181 (pg/mL), follow-up 32  13
Annual change,  (SE) 0.2 (1.2)
Isoprostane (pg/mL), baselinea 15.2  4.7
Isoprostane (pg/mL), follow-up 19.8  9.8
Annual change,  (SE) 1.9 (0.9)
NfL (ng/mL), baseline 5.0  4.6
NfL (ng/mL), follow-up 5.4  5.9
Annual change,  (SE) 0.18 (0.50)
NfH (pg/mL), baseline 404  147
NfH (pg/mL), follow-up 412  174
Annual change,  (SE) 1.5 (19.9)
A40 (ng/mL), baseline 9.6  3.0
A40 (ng/mL), follow-up 11.0  2.9
Annual change,  (SE) 0.61 (0.22)
Data are represented as mean  SD or  (SE). Linear mixed models wer
and change in CSF biomarker levels over time (in years). A random interc
were performed with diagnosis as categorical variable and time as continu
alculated with the linear mixed model. In this model, the main effect of d
epresents the annual change of biomarker levels for each diagnostic catego
mplying that the estimated time effects did not differ significantly by diagno
ey: A40, amyloid-beta n-40; A42, amyloid-beta 1-42; AD, Alzheimer
mpairment; NfH, neurofilaments heavy; NfL, neurofilaments light; ptau-1
a For isoprostane data was available for 21 nondemented patients, 61 M
* p  0.05 vs. nondemented subjects.
** p  0.005 vs. nondemented subjects.
*** p  0.005 vs. MCI patients.r ptau-181. Estimated annual changes by diagnosis group
re represented in Table 2 (no significant interactions diag-
osis  time). Levels of CSF isoprostane increased over
ime in all diagnosis groups, with an estimated annual in-
rease in isoprostane levels of 1.9 pg/mL in nondemented
atients, 2.3 pg/mL in MCI patients, and 1.9 pg/mL in AD
atients. Levels of NfL decreased over time in AD and MCI
atients, but not in nondemented subjects. Levels of NfH
ecreased over time, albeit nonsignificantly in AD patients,
ut not in MCI patients or nondemented subjects. CSF
evels of A40 increased in all patient groups, and CSF
levels of tau increased in MCI and AD patients. Fig. 1
shows the standardized ’s of the CSF biomarkers that
showed change over time, to allow comparison of effect
sizes; isoprostane had the largest effect size.
Secondly, we examined whether disease progression in
MCI patients was associated with change in biomarker
levels. We analyzed the effect of MCI subgroups (stable vs.
progressing to AD) on the change of CSF biomarker levels
over time. There were baseline effects of MCI subgroups for
CSF A42, tau, and ptau-181 (all p 0.005), but not for the
ther, nonspecific CSF biomarkers. By contrast, for isopros-
ane and for A40 we found that change of levels over time
MCI (n  62) AD (n  68)
307  114** 263  83**,***
315  119 273  78
0.4 (3.5) 5.0 (3.7)
155  109* 156  87**
172  122 189  89
5.8 (2.6) 5.6 (2.7)
42  29 43  26*
45  31 48  24
0.7 (1.0) 0.0 (1.1)
15.7  5.0 14.6  4.3
20.3  8.6 18.1  7.7
2.3 (0.5) 1.9 (0.5)
5.4  4.6 5.6  4.4
4.0  4.0 3.9  3.5
0.79 (0.31) 0.96 (0.31)
471  206 475  316
458  185 422  178
5 (13) 24 (13)
9.5  3.2 8.5  2.8*
10.0  3.1 9.2  3.4
0.28 (0.14) 0.43 (0.14)
d to assess the associations between diagnosis, baseline CSF biomarkers
a random slope with time were assumed. Age and sex adjusted analyses
iable, with an interaction term for diagnosis  time.  and p values were
s represents the group differences at baseline, and the main effect of time
interaction of diagnosis  time was not significant for any of the markers,
se; CSF, cerebrospinal fluid; iPF2-VI, isoprostane; MCI, mild cognitive
phosphorylated at threonine 181; SE, standard error; tau, total tau.
ents and 64 AD patients.24)
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tients (p for interaction both  0.05), whereas for the other
SF biomarkers effects were the same for MCI stable and
rogressive patients. Isoprostane levels increased in MCI pro-
ressive patients ( [SE] 3.8 [0.8]), while CSF isoprostane
evels hardly changed in stable MCI patients ( [SE] 0.9
[1.0]), as shown in Fig. 2. Contrary to our expectations,
A40 levels increased in MCI stable patients ( [SE] 0.55
[0.16]), but not in MCI progressors ( [SE] 0.07 [0.12]).
Next, we investigated whether change in CSF biomarker
levels over time was associated with cognitive decline, as an
indicator of clinical disease progression. For all biomarkers
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Fig. 1. Standardized time effects of the CSF biomarkers by diagnosis. B
onfidence interval [CI]). Linear mixed models were applied to assess
SF biomarker levels () over time (in years). A random intercept and
performed with diagnosis as categorical variable and time as continuous
ere calculated with the formula  biomarker  SD time/SD biomark
40, amyloid-beta n-40; AD, Alzheimer’s disease; CSF, cerebrospin
neurofilaments light; tau, total tau.that showed significant change over time, we performedlinear regression analyses to evaluate the association of
change in CSF biomarker levels with change of MMSE over
time. Annual change in isoprostane levels was associated
with annual MMSE change, as shown in Fig. 3:  (SE) were
0.11 (0.06) in nondemented (n16; p  0.08), 0.11
(0.05) in MCI (n  54; p  0.05) and 0.11 (0.04) in AD
(n  53; p  0.05). For the other CSF biomarkers, there
were no associations with cognitive decline:  (SE) of NfL
ere 0.11 (0.17) for nondemented (n 19), 0.10 (0.09)
for MCI (n  55) and 0.11 (0.10) for AD (n  56); for
A40 0.23 (0.32), 0.06 (0.29), and 0.03 (0.21); for tau
0.010 (0.13), 0.008 (0.009), and 0.004 (0.010); all p 
MCI
AD
Non-Demented
resent change in biomarker level over time (standardized  with 95%
ociations between diagnosis, baseline CSF biomarkers, and change in
m slope with time were assumed. Age- and sex-adjusted analyses were
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stimate and compare the effect sizes of the different CSF biomarkers.
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We found that 4 nonspecific CSF biomarkers, i.e., iso-
prostane, A40, tau, and NfL, showed change over time in
AD. Of these biomarkers, isoprostane appeared to be the
most promising marker for monitoring of disease progres-
sion, because it had the largest effect size. In addition,
increase over time of isoprostane levels was associated with
progression of MCI to AD, and increase of isoprostane was
associated with cognitive decline over time.
With the development of symptom-modifying drugs it is
of utmost importance to find biomarkers that allow for the
monitoring of disease progression of AD. Most previous
longitudinal studies examined only the CSF biomarkers
A42, tau, and ptau-181 (Blennow et al., 2007; Bouwman
et al., 2007; Buchhave et al., 2009; Li et al., 2007; Mollen-
hauer et al., 2005). Longitudinal effects of these specific
markers were disappointing, as was also illustrated by a
recent meta-analysis of these studies (Zhou et al., 2009). In
the current study we used Luminex technology for the
longitudinal measurement which did not seem to be an
added value over enzyme-linked immunosorbent assay, as
there were no changes in CSF A42 and ptau-181 levels
ver time, while CSF tau levels increased only minimally
ith disease progression. These findings are in line with the
dea that these AD-specific markers are state markers (Per-
in et al., 2009).
In the current study, we found that isoprostane, NfH,
fL, A40, and tau were all associated with disease pro-
ression in AD, with the strongest effect for isoprostane.
urthermore, increase of isoprostane levels was associated
ith progression of MCI to AD and cognitive decline, as
easured by repeated MMSE. The findings of our study are
upported by a few small studies in MCI and AD patients
hat also showed increase of isoprostane over time (Brys et
-2
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Fig. 2. Time effects by mild cognitive impairment (MCI) subgroups. Bars
represent change in isoprostane over time ( with 95% confidence interval
CI]). A linear mixed model was used with cerebrospinal fluid (CSF)
soprostane as dependent variable and age, sex, time, MCI subgroup (dum-
ies for MCI stable and MCI progression), and interaction terms (dummy
CI subgroup  time) were entered as covariates. There was a significant
nteraction of MCI subgroup  time.l., 2009; de Leon et al., 2007; Quinn et al., 2004). Isopros- mane is a marker of membrane lipid peroxidation and in-
ammation and previous data suggested that an increase of
SF isoprostane levels in cognitively declining patients
eflected progressive neuronal oxidative stress and progres-
ion of neurodegenerative changes (Pratico and Sung,
004).
NfL as measured with the current assay (and to a lesser
xtent also NfH) decreased over time in MCI and AD, but
ot in nondemented patients. However, we were not able to
stablish a relation with cognitive decline as measured with
MSE. Possibly, the decrease in neurofilament levels over
ime reflects the presence and progression of atrophy. Our
ndings should be examined in relation to MRI results and
ostmortem findings in future studies.
A40 increased over time in our study. Former studies
that examined longitudinal effects of A40 found no effect
over time, but these studies included small patient groups
and used a different test for the measurement of A40 (Brys
et al., 2009; Kanai et al., 1999; Mollenhauer et al., 2005).
The increase in A40 levels possibly reflects the increase of
olid, less diffuse, types of amyloid plaques, that generally
evelop in later stages of AD (Iwatsubo et al., 1994). Un-
xpectedly, in MCI patients we found the largest increase in
40 levels in those patients that did not progress to AD.
Possibly, in these stable MCI patients there was an in-
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Fig. 3. Associations of change in isoprostane levels over time and cognitive
decline. Associations between annualized change in cerebrospinal fluid
(CSF) isoprostane levels and annualized change in Mini Mental State
Examination (MMSE) score were assessed using linear regression models
(data available for 130 patients), adjusted for sex, age, and diagnosis. We
calculated the annualized change of CSF biomarker level and MMSE, with
the formula: value of measurement at follow-up minus value of measure-
ment at baseline, divided by follow-up period in years. The light gray line
and circles represent nondemented subjects ( [SE]0.11 [0.06]), the dark
ray line and triangles represent mild cognitive impairment (MCI) patients
 [SE] 0.11 [0.05]), and the black line and squares represent Alzhei-
er’s disease (AD) patients ( [SE] 0.11 [0.04]).
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ith a lack of formation of compact A plaques, as seen in
AD. However, the rise in A40 levels may also be unrelated
to AD pathology, and related to for instance vascular pa-
thology, which is not necessarily related to clinical deteri-
oration. The current study was not designed for analyzing
relations between biomarker level change, disease progres-
sion, and vascular pathology. Further studies could examine
correlations between changes in biomarker levels and in-
crease of for instance white matter hyperintensities (WMH)
at follow-up MRI.
Lastly, CSF tau levels showed some increase over time
during disease progression. CSF tau has been suggested to
reflect the degree of neuronal cell death and to be a more
general marker for neuronal damage (Arai et al., 1997;
Buerger et al., 2006; Hesse et al., 2001; Riemenschneider et
al., 2003; van der Vlies et al., 2009). Effects, however, were
modest and the cross-sectional difference between diagnosis
groups exceeded by far the longitudinal changes within
individuals.
We studied a panel of potential CSF biomarkers to mon-
itor disease progression in a large group of memory clinic
patients. Most of these biomarkers have only been evaluated
in small patient groups before, and some have never been
studied serially in AD. Our study allowed comparison of all
biomarkers, because they were measured in the same pa-
tients at the same time points. We have included patients of
all stages of the AD disease spectrum, including nonde-
mented subjects, MCI patients, and AD patients. We had
expected that effects would have been diagnosis-specific for
more biomarkers. The fact that there were no diagnosis-
specific effects seemingly cannot be explained by age. First,
there were only correlations between age and biomarker
level for isoprostane and NfL. Second, all analyses were
adjusted for age. A potential explanation could be that the
group of nondemented subjects (n  24) was too small in
comparison to the groups of MCI (n  62) and AD patients
(n  68) for adequate analyses, which could be considered
limitation. An alternative explanation could be that the
roup of nondemented subjects were in a prodromal stage of
D. Some of the patients in the group of nondemented
ubjects developed MCI or even dementia during follow-up.
he latter explanation is supported by our finding that iso-
rostane increase was associated with a decrease in MMSE
core, even in the nondemented subjects. For further studies
e aim to include a larger group of controls, preferably
ommunity dwelling volunteers with both cognitive and
iomarker follow-up.
These results imply that once a patient has developed the
ore AD pathological hallmarks of amyloid plaques and
angles to a certain extent, other nonspecific processes like
euronal cell and synaptic loss, as well as oxidative stress
re characteristic for disease progression. These less specific
rocesses are the disease processes to be monitored in
tudies focusing on disease progression. The results of thisind of studies could possibly also provide suggestions for
reatment options for later stages of AD pathology. It could
e hypothesized that therapies that focus on reducing the
onspecific pathogenic process, instead of intervening in
myloid accumulation, could be of benefit for patients at the
tage of clinical AD.
isclosure statement
Prof. Scheltens has served as consultant for Wyeth-Elan,
enentech, Danone, and Novartis, and received funding for
ravel from Pfizer, Elan, Janssen, and Danone Research. Dr.
eunissen has served as board member for Innogenetcs
nd the NeuroAdvisory Board for which she received con-
ultancy fees. Drs. Kester, Scheffer, Koel-Simmelink,
waalfhoven, Verwey, Veerhuis, Bouwman, Van der Flier,
nd Profs. Twisk and Blankenstein report no disclosures.
The study was approved by the local ethical review
oard and all subjects gave written informed consent.
cknowledgements
The Alzheimer Center Vumc is supported by Alzheimer
ederland and Stichting Vumc fonds. The clinical database
tructure was developed with funding from Stichting Dio-
aphte. Stichting De Merel supported the expenses of CSF
iomarker measurements. We thank Carsten Korth, who has
indly provided the antibodies for the NfH assay. We thank
ls van Deventer for her help in retrieving references.
eferences
Arai, H., Morikawa, Y., Higuchi, M., Matsui, T., Clark, C.M., Miura, M.,
Machida, N., Lee, V.M., Trojanowski, J.Q., Sasaki, H., 1997. Cerebro-
spinal fluid tau levels in neurodegenerative diseases with distinct tau-
related pathology. Biochem. Biophys. Res. Commun. 236, 262–264.
Blennow, K., Hampel, H., 2003. CSF markers for incipient Alzheimer’s
disease. Lancet Neurol. 2, 605–613.
Blennow, K., Zetterberg, H., Minthon, L., Lannfelt, L., Strid, S., Annas, P.,
Basun, H., Andreasen, N., 2007. Longitudinal stability of CSF bio-
markers in Alzheimer’s disease. Neurosci. Lett. 419, 18–22.
Bouwman, F.H., Schoonenboom, N.S., Verwey, N.A., van Elk, E.J., Kok,
A., Blankenstein, M.A., Scheltens, P., van der Flier, W.M., 2009. CSF
biomarker levels in early and late onset Alzheimer’s disease. Neuro-
biol. Aging 30, 1895–1901.
Bouwman, F.H., van der Flier, W.M., Schoonenboom, N.S., van Elk, E.J.,
Kok, A., Rijmen, F., Blankenstein, M.A., Scheltens, P., 2007. Longi-
tudinal changes of CSF biomarkers in memory clinic patients. Neurol-
ogy 69, 1006–1011.
Bouwman, F.H., van der Flier, W.M., Schoonenboom, N.S., van Elk, E.J.,
Kok, A., Scheltens, P., Blankenstein, M.A., 2006. Usefulness of lon-
gitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of
patients with various cognitive and neurologic disorders. Clin. Chem.
52, 1604–1606.
Brys, M., Pirraglia, E., Rich, K., Rolstad, S., Mosconi, L., Switalski, R.,
Glodzik-Sobanska, L., de, S.S., Zinkowski, R., Mehta, P., Pratico, D.,
Saint Louis, L.A., Wallin, A., Blennow, K., de Leon, M.J., 2009.
Prediction and longitudinal study of CSF biomarkers in mild cognitive
impairment. Neurobiol. Aging 30, 682–690.
1598 M.I. Kester et al. / Neurobiology of Aging 33 (2012) 1591–1598Buchhave, P., Blennow, K., Zetterberg, H., Stomrud, E., Londos, E.,
Andreasen, N., Minthon, L., Hansson, O., 2009. Longitudinal study of
CSF biomarkers in patients with Alzheimer’s disease. PLoS. One. 4,
e6294.
Buerger, K., Otto, M., Teipel, S.J., Zinkowski, R., Blennow, K., DeBer-
nardis, J., Kerkman, D., Schroder, J., Schonknecht, P., Cepek, L.,
McCulloch, C., Moller, H.J., Wiltfang, J., Kretzschmar, H., Hampel,
H., 2006. Dissociation between CSF total tau and tau protein phos-
phorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol.
Aging 27, 10–15.
de Jong, D., Kremer, B.P., Olde Rikkert, M.G., Verbeek, M.M., 2007.
Current state and future directions of neurochemical biomarkers for
Alzheimer’s disease. Clin. Chem. Lab Med. 45, 1421–1434.
de Leon, M.J., Mosconi, L., Li, J., de, S.S., Yao, Y., Tsui, W.H., Pirraglia,
E., Rich, K., Javier, E., Brys, M., Glodzik, L., Switalski, R., Saint
Louis, L.A., Pratico, D., 2007. Longitudinal CSF isoprostane and MRI
atrophy in the progression to AD. J. Neurol. 254, 1666–1675.
Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele,
H., Vanmechelen, E., Blennow, K., 2001. Transient increase in total tau
but not phospho-tau in human cerebrospinal fluid after acute stroke.
Neurosci. Lett. 297, 187–190.
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., Ihara, Y.,
1994. Visualization of A beta 42(43) and A beta 40 in senile plaques
with end-specific A beta monoclonals: evidence that an initially depos-
ited species is A beta 42(43). Neuron 13, 45–53.
Jack, C.R., Jr., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S.,
Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., 2010. Hypothetical
model of dynamic biomarkers of the Alzheimer’s pathological cascade.
Lancet Neurol. 9, 119–128.
Kanai, M., Shizuka, M., Urakami, K., Matsubara, E., Harigaya, Y., Oka-
moto, K., Shoji, M., 1999. Apolipoprotein E4 accelerates dementia and
increases cerebrospinal fluid tau levels in Alzheimer’s disease. Neuro-
sci Lett. 267, 65–68.
Kumar-Singh, S., 2008. Cerebral amyloid angiopathy: pathogenetic mech-
anisms and link to dense amyloid plaques. Genes Brain Behav. 7 Suppl
1, 67–82.
Li, G., Sokal, I., Quinn, J.F., Leverenz, J.B., Brodey, M., Schellenberg,
G.D., Kaye, J.A., Raskind, M.A., Zhang, J., Peskind, E.R., Montine,
T.J., 2007. CSF tau/Abeta42 ratio for increased risk of mild cognitive
impairment: a follow-up study. Neurology 69, 631–639.
McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O’Brien, J.T., Feld-
man, H., Cummings, J., Duda, J.E., Lippa, C., Perry, E.K., Aarsland,
D., Arai, H., Ballard, C.G., Boeve, B., Burn, D.J., Costa, D., Del, S.T.,
Dubois, B., Galasko, D., Gauthier, S., Goetz, C.G., Gomez-Tortosa, E.,
Halliday, G., Hansen, L.A., Hardy, J., Iwatsubo, T., Kalaria, R.N.,
Kaufer, D., Kenny, R.A., Korczyn, A., Kosaka, K., Lee, V.M., Lees,
A., Litvan, I., Londos, E., Lopez, O.L., Minoshima, S., Mizuno, Y.,
Molina, J.A., Mukaetova-Ladinska, E.B., Pasquier, F., Perry, R.H.,
Schulz, J.B., Trojanowski, J.Q., Yamada, M., 2005. Diagnosis and
management of dementia with Lewy bodies: third report of the DLB
Consortium. Neurology 65, 1863–1872.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan,
E.M., 1984. Clinical diagnosis of Alzheimer’s disease: report of the
NINCDS-ADRDA Work Group under the auspices of Department of
Health and Human Services Task Force on Alzheimer’s Disease. Neu-
rology 34, 939–944.
Mollenhauer, B., Bibl, M., Trenkwalder, C., Stiens, G., Cepek, L., Stein-
acker, P., Ciesielczyk, B., Neubert, K., Wiltfang, J., Kretzschmar, H.A.,
Poser, S., Otto, M., 2005. Follow-up investigations in cerebrospinal
fluid of patients with dementia with Lewy bodies and Alzheimer’s
disease. J Neural Transm. 112, 933–948.Montine, T.J., Quinn, J.F., Montine, K.S., Kaye, J.A., Breitner, J.C., 2005.
Quantitative in vivo biomarkers of oxidative damage and their appli-
cation to the diagnosis and management of Alzheimer’s disease. J
Alzheimers Dis. 8, 359–367.
Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S.,
Freedman, M., Kertesz, A., Robert, P.H., Albert, M., Boone, K., Miller,
B.L., Cummings, J., Benson, D.F., 1998. Frontotemporal lobar degen-
eration: a consensus on clinical diagnostic criteria. Neurology 51,
1546–1554.
Norgren, N., Rosengren, L., Stigbrand, T., 2003. Elevated neurofilament
levels in neurological diseases. Brain Res. 987, 25–31.
Norgren, N., Sundstrom, P., Svenningsson, A., Rosengren, L., Stigbrand,
T., Gunnarsson, M., 2004. Neurofilament and glial fibrillary acidic
protein in multiple sclerosis. Neurology 63, 1586–1590.
Perrin, R.J., Fagan, A.M., Holtzman, D.M., 2009. Multimodal techniques
for diagnosis and prognosis of Alzheimer’s disease. Nature 461, 916–
922.
Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G.,
Kokmen, E., 1999. Mild cognitive impairment: clinical characterization
and outcome. Arch Neurol. 56, 303–308.
Petzold, A., 2005. Neurofilament phosphoforms: surrogate markers for
axonal injury, degeneration and loss. J Neurol Sci. 233, 183–198.
Pijnenburg, Y.A., Janssen, J.C., Schoonenboom, N.S., Petzold, A., Mulder,
C., Stigbrand, T., Norgren, N., Heijst, H., Hack, C.E., Scheltens, P.,
Teunissen, C.E., 2007. CSF neurofilaments in frontotemporal dementia
compared with early onset Alzheimer’s disease and controls. Dement
Geriatr Cogn Disord. 23, 225–230.
Pratico, D., Sung, S., 2004. Lipid peroxidation and oxidative imbalance:
early functional events in Alzheimer’s disease. J Alzheimers Dis. 6,
171–175.
Quinn, J.F., Montine, K.S., Moore, M., Morrow, J.D., Kaye, J.A., Montine,
T.J., 2004. Suppression of longitudinal increase in CSF F2-isoprostanes
in Alzheimer’s disease. J Alzheimers Dis. 6, 93–97.
Riemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wilt-
fang, J., Kretzschmar, H., Vanmechelen, E., Forstl, H., Kurz, A., 2003.
Phospho-tau/total tau ratio in cerebrospinal fluid discriminates
Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 8,
343–347.
Roest, M., Voorbij, H.A.M., Van der Schouw, Y.T., Peeters, P.H.M.,
Teerlink, T., Scheffer, P.G., 2008. High levels of urinary F2-isopros-
tanes predict cardiovascular mortality in postmenopausal women.
J Clin Lipidol. 2, 298–303.
Román, G.C., Tatemichi, T.K., Erkinjuntti, T., Cummings, J.L., Masdeu,
J.C., Garcia, J.H., Amaducci, L., Orgogozo, J.M., Brun, A., Hofman,
A., et al., 1993. Vascular dementia: diagnostic criteria for research
studies. Report of the NINDS-AIREN International Workshop. Neu-
rology 43, 250–260.
van der Vlies, A.E., Verwey, N.A., Bouwman, F.H., Blankenstein, M.A.,
Klein, M., Scheltens, P., van der Flier, W.M., 2009. CSF biomarkers in
relationship to cognitive profiles in Alzheimer disease. Neurology 72,
1056–1061.
Verwey, N.A., Bouwman, F.H., van der Flier, W.M., Veerhuis, R., Schel-
tens, P., Blankenstein, M.A., 2008. Variability in longitudinal cerebro-
spinal fluid tau and phosphorylated tau measurements. Clin Chem Lab
Med. 46, 1300–1304.
Verwey, N.A., Veerhuis, R., Twaalfhoven, H.A., Wouters, D., Hoozemans,
J.J., Bollen, Y.J., Killestein, J., Bibl, M., Wiltfang, J., Hack, C.E.,
Scheltens, P., Blankenstein, M.A., 2009. Quantification of amyloid-
beta 40 in cerebrospinal fluid. J Immunol Methods 348, 57–66.
Zhou, B., Teramukai, S., Yoshimura, K., Fukushima, M., 2009. Validity of
cerebrospinal fluid biomarkers as endpoints in early-phase clinical
trials for Alzheimer’s disease. J Alzheimers Dis. 18, 89–102.
